{"id": "370701", "url": "https://fevir.net/resources/Group/370701", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-exposure-definition"], "versionId": "2", "lastUpdated": "2025-05-28T13:31:45.515Z"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p>[No data.]</p></div>", "status": "empty"}, "type": "person", "title": "Glucagon Nasal Powder (Experimental)", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as", "valueMarkdown": "Glucagon Nasal Powder (Experimental) [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370701. Revised 2025-05-28. Available at: https://fevir.net/resources/Group/370701. Computable resource at: https://fevir.net/resources/Group/370701#json."}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Brian S. Alper, MD, MSPH"}}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "370701", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}], "membership": "conceptual", "description": "Example of ConceptualExposureDefinition combining M11 IGBJ Protocol Example Eligibility Criteria PLUS exposure to Glucagon Nasal Powder", "resourceType": "Group", "characteristic": [{"code": {"text": "Member of"}, "exclude": false, "description": "Member of M11 IGBJ Protocol Example Eligibility Criteria", "valueReference": {"type": "Group", "display": "M11 IGBJ Protocol Example Eligibility Criteria", "reference": "Group/267506"}}, {"code": {"text": "Assigned to"}, "exclude": false, "description": "assigned to Glucagon Nasal Powder", "valueCodeableConcept": {"text": "Glucagon Nasal Powder (Experimental) A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally."}}], "combinationMethod": "all-of"}